While neoadjuvant ICB administration in recurrent glioblastoma may capitalize on increased T cell infiltration and cDC1 activation4,18, our results exposed a therapeutic window post-RT for primary glioblastoma treatment. This evidence concerns the gene MPPE1 and glioblastoma.